Amerikanische Gesellschaft für Hirudotherapie

Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway

Mechanism study published in Drug Design, Development and Therapy (2020)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genomik & ProteomikSpeichel-PharmakologieHan J et al. · Drug design, development and therapy, 2020

Abstract

BACKGROUND: Inflammation-induced podocyte apoptosis plays an important role in kidney injury during diabetic nephropathy (DN). Hirudin (HIR), a natural compound extracted from leeches, can inhibit inflammation. However, whether HIR can protect the kidneys against inflammation during DN is unknown. In the present study, we aimed to study the effects of HIR on kidney damage in a DN rat model and explore its anti-inflammatory properties. METHODS: A streptozotocin-induced DN rat model was generated, and HIR was administered subcutaneously. Immortal podocytes and primary peritoneal macrophages were used for vitro studies. Hematoxylin and eosin staining was used to evaluate renal pathological changes; quantitative polymerase chain reaction and immunoblotting were used to detect gene expression; and TUNEL staining was used to detect apoptotic cells. RESULTS: Our results showed that HIR protected against renal injury, as indicated by kidney weight/body weight, serum creatinine, renal pathological changes, blood urea nitrogen, and detection of urine proteins. Notably, HIR treatment reduced macrophage infiltration, pro-inflammatory cytokine expression, and podocyte apoptosis in the kidney tissues of DN rats. In vitro, high glucose (HG) induced the activation of M1 macrophages, which was accompanied by increased podocyte apoptosis. HIR could decrease HG-induced podocyte apoptosis and suppress pro-inflammatory cytokine expression in podocytes in vitro. This was achieved via inhibition of p38 MAPK/NF-κB activation in renal tissues and podocytes. CONCLUSION: HIR could inhibit inflammation via the p38 MAPK/NF-κB pathway, prevent podocyte apoptosis, and protect against kidney damage in a DN rat model.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsApoptosisDiabetic NephropathiesDisease Models, AnimalHirudinsInflammationInjections, SubcutaneousKidneyLeechesMacrophagesMaleNF-kappa B

Zusammenfassung

Hirudin protects against renal damage in STZ-diabetic rats by inhibiting inflammation via P38 MAPK/NF-κB pathway — mechanistic basis for leech-hirudin anti-inflammatory action.

Warum dies für die Hirudotherapie relevant ist

This study examined whether hirudin (HIR), a compound extracted from leeches, could protect against kidney damage in a streptozotocin-induced diabetic nephropathy (DN) rat model by inhibiting inflammation via the p38 MAPK/NF-κB pathway. Hirudin reduced macrophage infiltration, pro-inflammatory cytokine expression, and podocyte apoptosis in DN rat kidneys; in vitro, it decreased high glucose-induced podocyte apoptosis and suppressed pro-inflammatory cytokine expression in podocytes, achieved via inhibition of p38 MAPK/NF-κB activation in renal tissues and podocytes. This is relevant to ASH's domain as it investigates the anti-inflammatory and renoprotective properties of a leech-extracted compound in a disease model. However, all findings derive from a DN rat model and in vitro cell studies; no human dosing, safety, or efficacy data are presented.

Zitation

Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway.

Han J et al. · Drug design, development and therapy, 2020

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.